Spero Therapeutics Inc (NAS:SPRO)
$ 1.45 0 (0%) Market Cap: 78.28 Mil Enterprise Value: 1.25 Mil PE Ratio: 3.30 PB Ratio: 0.81 GF Score: 40/100

Spero Therapeutics Inc R&D Event Transcript

Oct 06, 2022 / 03:30PM GMT
Release Date Price: $2.07 (-1.43%)
Operator

Good morning, and welcome to the Spero Therapeutics R&D Day. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Spero website following the conclusion of the event. I'd now like to turn the call over to Ted Jenkins, Vice President and Head of Investor Relations at Spero Therapeutics. Please go ahead, Ted.

Ted Jenkins
Spero Therapeutics, Inc. - VP & Head of IR

Thank you, Tara, and thank you all for participating in today's discussion on non-tuberculous mycobacterial or NTM pulmonary disease along with the Spero presentation of SPR720, our novel first-line candidate, broad spectrum oral antibacterial agent in development to treat NTM infections. Before we begin, I'd like to remind you that some of the information presented on this conference call contains certain forward-looking statements based on our current expectations, including statements with the future development and commercialization of SPR720, SPR206 and tebipenem HBr, and the design, initiation, timing, progress and results of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot